Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation

Share-based compensation

6 Months Ended

Jun. 30, 2024

Note 11 — Share-based compensation

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):


		Three months ended			Six months ended
		June 30,			June 30,
	2024		2023		2024		2023
Research and development	$	994	$	1,285	$	1,808	$	1,401
General and administrative		2,063		2,552		4,352		4,112
	$	3,057	$	3,837	$	6,160	$	5,513

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:


		Three months ended			Six months ended
		June 30,			June 30,
	2024		2023		2024		2023
Number of options over ordinary shares granted		1,795,872		30,247,398		43,982,424		52,002,726
Weighted average fair value of ordinary shares options	$	0.19	$	0.05	$	0.12	$	0.08
Number of additional options with a nominal exercise price granted		2,540,640		6,148,186		30,655,824		26,015,098
Weighted average fair value of options with a nominal exercise price	$	0.24	$	0.15	$	0.15	$	0.17